FDA has approved both Takeda’s HYQVIA, a new maintenance therapy for patients with CIDP, and GAMMAGARD LIQUID®. The Foundation advocates for access to all products at all points of care. As always, the Foundation recommends consulting with your physician when exploring new treatment options.
More information at our HYQVIA Treatment and Access Page: https://www.gbs-cidp.org/treatments-access/takeda/
Approval of GAMMAGARD LIQUID®. Press Release: https://www.takeda.com/en-us/newsroom/news-releases/2024/takedas-gammagard-liquid-approved-for-adults-with-cidp-in-united-states
Statement from Global Medical Advisor, Dr. Jeffrey Allen
Dr. Jeffry Allen states, “The approval of HYQVIA provides patients with CIDP a new treatment option. HYQVIA is a subcutaneous infusion therapy that is unique in that it combines immunoglobulin with hyaluronidase. This combination allows for an increased volume of immunoglobulin to be administered into the subcutaneous tissues with each infusion. In a large randomized, double-blinded placebo-controlled clinical trial, it was demonstrated that HYQVIA was safe and effective for the prevention of relapse when used as a maintenance therapy. Most patients in the clinical trial received a subcutaneous infusion every 2 to 4 weeks. This new option adds to the repertoire of treatments that are available to those with CIDP. It is important to talk to your neurologist to discuss which option is best for you, but with this approval, we have more flexibility to customize maintenance therapies to meet the needs of individual people on treatment for CIDP.”